Novel Radially Adjustable Stent retriever Effectively Treats Acute Ischemic Stroke

The major outcomes assessed were:

Efficacy outcome: Successful reperfusion, determined as core laboratory-adjudicated modified Thrombolysis in Cerebral Ischemia (mTICI) score 2b-3 within three passes of the Tigertriever.

The researchers also assessed the 3-month good clinical outcome (modified Rankin Scale 0-2) and first-pass successful reperfusion.

Safety outcome: Composite of 90-day all-cause mortality and symptomatic intracranial haemorrhage (sICH).

Key findings of the study were:

• Upon analysis, the researchers noted that the primary efficacy endpoint was achieved in 84.6% in the main-study phase group compared with the 63.4% performance goal and the 73.4% historical rate. The first pass successful reperfusion rate was 57.8%.
• After all interventions, they noted that successful reperfusion (mTICI ≥2b) was achieved in 95.7% and excellent reperfusion (mTICI 2c-3) in 71.8%.
• In terms of safety outcome, they found that the rate of mortality and sICH was 18.1% compared with the 30.4% performance goal and the 20.4% historical rate.
• They also noted that Good functional status at 90 days, defined by a modified Rankin Scale (mRS) score of 0 to 2, was achieved by 58% of patients, superior to the historical control rate of 43%.

The authors concluded, "The Tigertriever device was shown to be highly effective and safe compared to Trevo and Solitaire devices to remove thrombus in large vessel occlusive stroke patients eligible for mechanical thrombectomy."

For further information:

https://www.ahajournals.org/doi/abs/10.1161/STROKEAHA.121.034436